Walking the tightrope of survival and quality of life with adt

A recent study has highlighted the risks and benefits associated with the administration of intermittent androgen deprivation therapy in patients with metastatic prostate cancer. Although

there are improvements in many quality-of-life domains, these improvements must be carefully weighed against the potential harms of intermittent androgen deprivation therapy in this patient

population. KEY POINTS The decision to administer intermittent or continuous androgen deprivation therapy to patients with metastatic prostate cancer must be individualized to reflect

patients' preferences surrounding various quality-of-life domains. Access through your institution Buy or subscribe This is a preview of subscription content, access via your

institution ACCESS OPTIONS Access through your institution Subscribe to this journal Receive 12 print issues and online access $209.00 per year only $17.42 per issue Learn more Buy this

article * Purchase on SpringerLink * Instant access to full article PDF Buy now Prices may be subject to local taxes which are calculated during checkout ADDITIONAL ACCESS OPTIONS: * Log in

* Learn about institutional subscriptions * Read our FAQs * Contact customer support REFERENCES * Alibhai, S. M. _ et al_. Impact of androgen-deprivation therapy on physical function and

quality of life in men with nonmetastatic prostate cancer. _J. Clin. Oncol._ 28, 5038–5045 (2010). Article  CAS  Google Scholar  * Sadetsky, N. _ et al_. Impact of androgen deprivation on

physical well-being in patients with prostate cancer: analysis from the CaPSURE (Cancer of the Prostate Strategic Urologic Research Endeavor) registry. _Cancer_ 117, 4406–4413 (2011).

Article  CAS  Google Scholar  * Hussain, M. _ et al_. Intermittent versus continuous androgen deprivation in prostate cancer. _N. Engl. J. Med._ 368, 1314–1325 (2013). Article  CAS  Google

Scholar  * Crook, J. M. _ et al_. Intermittent androgen suppression for rising PSA level after radiotherapy. _N. Engl. J. Med._ 367, 895–903 (2012). Article  CAS  Google Scholar  * Calais da

Silva, F. E. _ et al_. Intermittent androgen deprivation for locally advanced and metastatic prostate cancer: results from a randomised phase 3 study of the South European Uroncological

Group. _Eur. Urol._ 55, 1269–1277 (2009). Article  CAS  Google Scholar  * Jaeschke, R., Singer, J. & Guyatt, G. H. Measurement of health status. Ascertaining the minimal clinically

important difference. _Control Clin. Trials_ 10, 407–415 (1989). Article  CAS  Google Scholar  * Juniper, E. F., Guyatt, G. H., Willan, A. & Griffith, L. E. Determining a minimal

important change in a disease-specific Quality of Life Questionnaire. _J. Clin. Epidemiol._ 47, 81–87 (1994). Article  CAS  Google Scholar  * Wells, G. A. _ et al_. Minimum important

difference between patients with rheumatoid arthritis: the patient's perspective. _J. Rheumatol._ 20, 557–560 (1993). CAS  PubMed  Google Scholar  * Norman, G. R., Sloan, J. A. &

Wyrwich, K. W. Interpretation of changes in health-related quality of life: the remarkable universality of half a standard deviation. _Med. Care_ 41, 582–592 (2003). PubMed  Google Scholar 

Download references ACKNOWLEDGEMENTS The author acknowledges support from the Veterans Affairs National Quality Scholars Program and the T. J. Martell Foundation, and the use of facilities

at Veterans Health Administration Tennessee Valley Healthcare System. AUTHOR INFORMATION AUTHORS AND AFFILIATIONS * Department of Urologic Surgery, Vanderbilt University Medical Center and

the Tennessee Valley Veterans Affairs Health Care System, 2525 West End Avenue, Suite 1200, Nashville, 37203, TN, USA Matthew J. Resnick Authors * Matthew J. Resnick View author publications

You can also search for this author inPubMed Google Scholar ETHICS DECLARATIONS COMPETING INTERESTS The author is a Consultant and Advisor for Dendreon Corporation. RIGHTS AND PERMISSIONS

Reprints and permissions ABOUT THIS ARTICLE CITE THIS ARTICLE Resnick, M. Walking the tightrope of survival and quality of life with ADT. _Nat Rev Clin Oncol_ 10, 307–308 (2013).

https://doi.org/10.1038/nrclinonc.2013.78 Download citation * Published: 07 May 2013 * Issue Date: June 2013 * DOI: https://doi.org/10.1038/nrclinonc.2013.78 SHARE THIS ARTICLE Anyone you

share the following link with will be able to read this content: Get shareable link Sorry, a shareable link is not currently available for this article. Copy to clipboard Provided by the

Springer Nature SharedIt content-sharing initiative